Similar articles

• [Anaphylactoid reaction caused by intravenous gadopentetate dimeglumine in magnetic resonance].

  Campos A, Aznar L, Alamar R, Castelló JV. Campos A, et al. Med Clin (Barc). 1996 Feb 10;106(5):197. Med Clin (Barc). 1996. PMID: 8684023 Spanish. No abstract available.
• Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine.

  Witte RJ, Anzai LL. Witte RJ, et al. AJNR Am J Neuroradiol. 1994 Mar;15(3):523-4. AJNR Am J Neuroradiol. 1994. PMID: 8197951 Free PMC article.
• Potential neurotoxic effects of gadopentetate dimeglumine: clinical significance.

  Alhassan A, Weinmann HJ. Alhassan A, et al. AJNR Am J Neuroradiol. 1997 Apr;18(4):785-6; author reply 786-8. AJNR Am J Neuroradiol. 1997. PMID: 9127052 Free PMC article. No abstract available.
• Distribution and chemical forms of gadolinium in the brain: a review.

  Kanda T, Nakai Y, Hagiwara A, Oba H, Toyoda K, Furui S. Kanda T, et al. Br J Radiol. 2017 Nov;90(1079):20170115. doi: 10.1259/bjr.20170115. Epub 2017 Sep 28. Br J Radiol. 2017. PMID: 28749164 Free PMC article. Review.
• The question of dose for gadolinium chelates in magnetic resonance imaging.

  Runge VM, Kirsch JE, Wells JW, Dunworth JN, Woolfolk CE. Runge VM, et al. Invest Radiol. 1994 Jun;29 Suppl 2:S154-6. doi: 10.1097/00004424-199406001-00051. Invest Radiol. 1994. PMID: 7928215 Review. No abstract available.